You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ACBD5-RET

Showing 1 - 25 of 340
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (LOXO-292)

Recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Scottsdale, Arizona
  • +84 more
Oct 10, 2022

Patients With Peroxisome Biogenesis Disorders (PBD)

Recruiting
  • Peroxisome Biogenesis Disorder
  • +10 more
    • Montreal, Quebec, Canada
      Research Institute of the McGill University Health Center
    Jul 4, 2022

    Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)

    Recruiting
    • Nonsmall Cell Lung Cancer
    • HS-10365 capsules
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Nov 22, 2023

    RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

    Active, not recruiting
    • RET-altered Non Small Cell Lung Cancer
    • +39 more
    • pralsetinib (BLU-667)
    • Phoenix, Arizona
    • +65 more
    Nov 10, 2022

    NSCLC Trial in Shanghai (SY-5007)

    Recruiting
    • Non-Small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Sep 4, 2023

    Medullary Thyroid Cancer Trial in Worldwide (Selpercatinib, Cabozantinib, Vandetanib)

    Recruiting
    • Medullary Thyroid Cancer
    • Birmingham, Alabama
    • +148 more
    Jan 18, 2023

    MDD Trial in Ames (Resistance Exercise Training)

    Active, not recruiting
    • Major Depressive Disorder
    • Resistance Exercise Training
    • Ames, Iowa
      Iowa State University
    Jan 12, 2023

    Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)

    Active, not recruiting
    Has Results
    • Solid Tumor
    • Medullary Thyroid Cancer
    • Guangzhou, Guangdong, China
    • +12 more
    May 9, 2022

    NSCLC Trial in Worldwide (Selpercatinib, Carboplatin, Cisplatin)

    Active, not recruiting
    • Non-Small Cell Lung Cancer
    • Berazategui, Buenos Aires, Argentina
    • +195 more
    Jan 30, 2023

    Advanced Nonhaematologic Malignancies Trial in Worldwide (BOS172738)

    Active, not recruiting
    • Advanced Nonhaematologic Malignancies
    • Philadelphia, Pennsylvania
    • +20 more
    Sep 23, 2022

    Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer Trial in Boston (Selpercatinib, Sodium Iodine I-131, rhTSH)

    Not yet recruiting
    • Thyroid Cancer
    • +5 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Dec 20, 2022

    Malignant Thyroid Gland Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma Trial in Houston

    Recruiting
    • Malignant Thyroid Gland Neoplasm
    • +6 more
    • Quality-of-Life Assessment
    • +3 more
    • Ann Arbor, Michigan
    • +1 more
    Jan 24, 2023

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    Eyelid Dermatochalasis, Dermatochalasis Trial in Miami (Restorative Eye Treatment (RET) cream, INhance with Trihex Technology)

    Active, not recruiting
    • Eyelid Dermatochalasis
    • Dermatochalasis
    • Restorative Eye Treatment (RET) cream
    • INhance with Trihex Technology
    • Miami, Florida
      Bascom Palmer Eye Institute, University of Miami
    May 16, 2022

    Hematopoietic and Lymphoid Cell Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States

    Recruiting
    • Hematopoietic and Lymphoid Cell Neoplasm
    • +37 more
    • Birmingham, Alabama
    • +171 more
    Aug 24, 2022

    NSCLC Trial in Guangzhou (HA121-28 tablet)

    Recruiting
    • NSCLC
    • HA121-28 tablet
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Centre
    Aug 2, 2022

    ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)

    Terminated
    Has Results
    • ALK-positive Non-small Cell Lung Cancer (NSCLC)
    • +2 more
    • Irvine, California
    • +3 more
    Aug 30, 2021

    Infected Immature Permanent Teeth Trial in Singapore (RET using antibiotics (Ciprofloxacin and Metronidazole), RET using

    Completed
    • Infected Immature Permanent Teeth
    • RET using antibiotics (Ciprofloxacin and Metronidazole)
    • RET using non-setting Calcium Hydroxide
    • Singapore, Singapore
    • +1 more
    Oct 13, 2021

    Medullary Thyroid Cancer Trial in Cordoba, Sevilla (Pralsetinib, Cabozantinib, Vandetanib)

    Not yet recruiting
    • Medullary Thyroid Cancer
    • Cordoba, Spain
    • +1 more
    Jan 11, 2023

    RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Chang chun

    Not yet recruiting
    • RET-altered Non Small Cell Lung Cancer
    • +3 more
    • Chang chun, Jilin, China
      Jinlin Province Cancer Hosipital
    Dec 21, 2022

    Solid Tumor Trial in Shanghai (HS-10365)

    Recruiting
    • Solid Tumor
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Jan 24, 2022

    Breast Cancer Trial in Singapore (Lenvatinib + Letrozole, Fulvestrant)

    Not yet recruiting
    • Breast Cancer
    • Singapore, Singapore
      Nationa University Hospital
    Jan 4, 2022

    Advanced Solid Tumor Trial in Los Angeles (EP0031)

    Recruiting
    • Advanced Solid Tumor
    • Los Angeles, California
    • +3 more
    Dec 1, 2022

    Refractory Solid Tumors Trial in Seoul (sunitinib)

    Completed
    • Refractory Solid Tumors
    • Seoul, Korea, Republic of
      Samsung Medical Center
    Jun 13, 2022

    NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Shanghai, Shanghai, China
    • +1 more
    Mar 17, 2022